News

If approved, PDS ranibizumab would become the first and only eye implant with continuous drug delivery offering people with wet AMD.

According to investigators, the system has been shown to almost triple the number of people with eye problems attending primary care, as well as increasing appropriate uptake of hospital services.

Postop management with long-term topical antibiotics is critical to successful device retention.

Oyster Point Pharma announced today the enrollment of the first participant in its OLYMPIA phase 2 clinical trial of OC-01 (varenicline) nasal spray to treat stage 1 neurotrophic keratopathy (NK).

Implandata received FDA Breakthrough Device Designation for its Eyemate-SC in April and now has CE Mark approval in the European Union.

The American Medical Association is advocating equitable resource distribution of vaccinations to assist low-income countries.

According to investigators, infants may have an edge over adults, with babies demonstrating a stronger immune response to the SARS-CoV-2 virus.

According to investigators, the new technology is designed to detect telltale signs of major blinding diseases in retinal blood and tissue that typically go unseen until it is too late.

The US Supreme Court ruled Thursday that the Affordable Care Act remains valid, rejecting a claim by several states that a recent change to the law made it unconstitutional.

The event, being held at the Mandalay Bay Resort and Casino in Las Vegas, is offering a full agenda for in-person attendees.

The American Academy of Ophthalmology is calling on its members to continue to build confidence in COVID-19 vaccines and encourage people to get vaccinated, including their staff.

Clearside Biomedical, Inc. reported today positive safety results from Cohort 1 of its ongoing OASIS phase1/2a clinical trial of CLS-AX for the treatment of wet AMD.

Classification criteria funded by the National Institutes of Health will facilitate clinical research for new therapies.

EyeGate Pharmaceuticals, Inc.'s lead product candidate is designed to treat dry eye disease-induced ocular surface inflammation.

Stuart will enroll 150 volunteers in the study, which is being conducted with the support of Stuart's strategic partner and CRO, Ora Clinical. ST-100 is based on PolyCol, the company's synthesized polypeptide tissue reparative platform.

Physicians want to make sure they see each their patient frequently enough not to miss important changes in eye disease.

According to the company, more than 400 eyes of patients from 12 European countries have been fitted with the TECNIS Eyhance Toric II IOL, with surgeons surveyed noting that their patients are pleased with the results.

Researchers seek to identify new serological biomarkers that could better characterize Sjogren’s syndrome and overcome the limitations of traditional antibodies.

According to the company, preclinical study results from a 42-day proof-of-concept in vivo study demonstrated a single, intralacrimal gland injection of an adeno-associated virus containing the NGF gene produced statistically significant increase in NGF in tear film, as compared to placebo, as early as Day 7.

More Americans have used and continue to use teleheath for mental health care. according to a recent online poll by the American Psychiatric Association.

Upsher-Smith Laboratories LLC and Rafarm SA have announced the U.S. commercial launch of moxifloxacin ophthalmic solution, USP 0.5% following a recent abbreviated new drug application (ANDA) approval by the FDA.

The company is hoping to commercialize the first FDA-approved ophthalmic formulation of bevacizumab-vikg for retinal disease. It expects to receive BLA approval from the FDA by mid-2022.

A new report by George Washington University offers a snapshot of health care workers during the COVID-19 pandemic and offers recommendations to prepare for the future.

Vyluma Inc. will focus on the development and commercialization of therapies to treat ophthalmic diseases, including pediatric myopia.

Backed by a five-year, $6.4 million grant from the National Eye Institute of the National Institutes of Health, investigators from Case Western Reserve University, University Hospitals and the Jaeb Center for Health Research hope to determine which diabetic patients can successfully donate their corneas for keratoplasty (and which should not).

The company plans to start a second Phase 3 registration study, VISION-2, as it continues on path toward a New Drug Application submission to the FDA.

A team of researchers at the University of Cincinnati's Department of Chemistry and Department of Ophthalmology, in collaboration with researchers at Cincinnati Children's Hospital Medical Center and the Ohio State University, have received a four-year, $1.6 million grant from the National Institutes of Health/National Eye Institute to develop a drug delivery system that is more efficient and longer lasting than conventional eye injections.

An international research team has shown that optogenetic therapy has helped to partially regain visual function in a patient with retinitis pigmentosa. This is a milestone towards a gene therapy that could restore vision.

A recent study may indicate the need for future research to assess the relationship between pain and the anterior chamber depth.

Dexamethasone implant is key to treating non-infectious posterior segment uveitis.